阿卡替尼单药或联合利妥昔单抗治疗滤泡性淋巴瘤：一项开放标签研究。
Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.
作者信息
Strati Paolo, Champion Rebecca, Coleman Morton, Smith Sonali M, Venugopal Parameswaran, Martin Peter, Wood Andrew, Miller Kara, Christian Beth
机构信息
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Norton Cancer Institute, Louisville, Kentucky, USA.
出版信息
Br J Haematol. 2024 Dec;205(6):2248-2253. doi: 10.1111/bjh.19787. Epub 2024 Sep 22.
Abstract
Acalabrutinib is a selective, second-generation Bruton tyrosine kinase inhibitor. In this open-label, parallel-group study, patients with relapsed/refractory (R/R) follicular lymphoma (FL) were randomised to either acalabrutinib monotherapy or acalabrutinib plus rituximab. An additional cohort of patients with treatment-naive (TN) FL received only the acalabrutinib-rituximab combination. Acalabrutinib-rituximab was well tolerated and active in R/R and TN FL; in the TN cohort the overall response rate was 92.3% with most remissions lasting over 4 years. Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.
摘要
阿卡替尼是一种选择性第二代布鲁顿酪氨酸激酶抑制剂。在这项开放标签、平行组研究中，复发/难治性（R/R）滤泡性淋巴瘤（FL）患者被随机分为阿卡替尼单药治疗组或阿卡替尼联合利妥昔单抗治疗组。另外一组初治（TN）FL患者仅接受阿卡替尼-利妥昔单抗联合治疗。阿卡替尼-利妥昔单抗耐受性良好，对R/R和TN FL均有活性；在TN队列中，总体缓解率为92.3%，大多数缓解持续超过4年。阿卡替尼单药治疗对R/R FL也具有良好的耐受性和活性。这些结果支持进一步研究阿卡替尼单药以及与利妥昔单抗联合用于FL的治疗。
相似文献
1
Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.阿卡替尼单药或联合利妥昔单抗治疗滤泡性淋巴瘤：一项开放标签研究。
Br J Haematol. 2024 Dec;205(6):2248-2253. doi: 10.1111/bjh.19787. Epub 2024 Sep 22.
2
Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).阿卡拉布替尼联合利妥昔单抗和来那度胺治疗复发或难治性滤泡性淋巴瘤患者：1b期开放标签研究（ACE-LY-003）结果
Br J Haematol. 2025 Mar;206(3):887-898. doi: 10.1111/bjh.19951. Epub 2024 Dec 12.
3
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.ASCEND：阿卡替尼对比伊布替尼联合利妥昔单抗或苯达莫司汀联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病的 III 期随机试验。
J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27.
4
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial.阿卡拉布替尼联合苯达莫司汀和利妥昔单抗治疗初治或复发/难治性套细胞淋巴瘤患者的安全性和有效性：Ib期试验
Haematologica. 2025 Mar 1;110(3):715-724. doi: 10.3324/haematol.2023.284896.
5
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease.STELLAR 试验方案：一项新诊断 RS 患者接受 CHOP-R 联合或不联合阿卡替尼的随机试验调查，以及复发疾病中新型药物评估的单臂平台研究组成的 Richter 综合征前瞻性多中心试验
BMC Cancer. 2019 May 20;19(1):471. doi: 10.1186/s12885-019-5717-y.
6
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.阿卡拉布替尼联合奥滨尤妥珠单抗治疗初治及复发/难治性慢性淋巴细胞白血病
Cancer Discov. 2020 Mar;10(3):394-405. doi: 10.1158/2159-8290.CD-19-1130. Epub 2020 Jan 8.
7
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.阿卡替尼联合维奈托克和利妥昔单抗治疗初治套细胞淋巴瘤：2 年安全性和疗效分析。
Blood Adv. 2024 Sep 10;8(17):4539-4548. doi: 10.1182/bloodadvances.2023012424.
8
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.阿卡替尼联合或不联合奥滨尤妥珠单抗对比苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（ELEVATE TN）：一项随机、对照、III 期临床试验。
Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.
9
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.套细胞淋巴瘤复发/难治患者中阿卡替尼与其他靶向治疗药物疗效和安全性的匹配调整间接比较。
Clin Ther. 2019 Nov;41(11):2357-2379.e1. doi: 10.1016/j.clinthera.2019.09.012. Epub 2019 Nov 4.
10
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.一项随机 II 期研究评估了布鲁顿酪氨酸激酶抑制剂阿卡替尼单药或联合帕博利珠单抗治疗晚期胰腺癌患者的疗效。
J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2020-000587.
引用本文的文献
1
Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).阿卡拉布替尼联合利妥昔单抗和来那度胺治疗复发或难治性滤泡性淋巴瘤患者：1b期开放标签研究（ACE-LY-003）结果
Br J Haematol. 2025 Mar;206(3):887-898. doi: 10.1111/bjh.19951. Epub 2024 Dec 12.
本文引用的文献
1
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.SELENE 研究 3 期：伊布替尼联合 BR/R-CHOP 方案治疗滤泡性或边缘区淋巴瘤患者。
Blood Adv. 2023 Nov 28;7(22):7141-7150. doi: 10.1182/bloodadvances.2023010298.
2
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.ROSEWOOD：泽布替尼联合奥滨尤妥珠单抗对比奥滨尤妥珠单抗单药治疗复发/难治滤泡性淋巴瘤患者的 II 期随机研究。
J Clin Oncol. 2023 Nov 20;41(33):5107-5117. doi: 10.1200/JCO.23.00775. Epub 2023 Jul 28.
3
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.复发/难治性滤泡性淋巴瘤的治疗模式和结局：来自国际 SCHOLAR-5 研究的结果。
Haematologica. 2023 Mar 1;108(3):822-832. doi: 10.3324/haematol.2022.281421.
4
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.泽布替尼单药治疗复发/难治性惰性非霍奇金淋巴瘤。
Blood Adv. 2022 Jun 14;6(11):3472-3479. doi: 10.1182/bloodadvances.2021006083.
5
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.布鲁顿酪氨酸激酶抑制剂在 B 细胞恶性肿瘤中的应用及其特点。
Target Oncol. 2022 Jan;17(1):69-84. doi: 10.1007/s11523-021-00857-8. Epub 2021 Dec 14.
6
Follicular lymphoma and macrophages: impact of approved and novel therapies.滤泡性淋巴瘤与巨噬细胞：已获批疗法和新型疗法的影响。
Blood Adv. 2021 Oct 26;5(20):4303-4312. doi: 10.1182/bloodadvances.2021005722.
7
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.现代滤泡性淋巴瘤：生存、治疗结果和高危亚组的识别。
Blood Cancer J. 2020 Jul 17;10(7):74. doi: 10.1038/s41408-020-00340-z.
8
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.伊布替尼治疗复发/难治性滤泡性淋巴瘤患者：来自开放标签、多中心、Ⅱ期 DAWN 研究的结果。
J Clin Oncol. 2018 Aug 10;36(23):2405-2412. doi: 10.1200/JCO.2017.76.8853. Epub 2018 May 31.
9
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.单药伊布替尼治疗复发或难治性滤泡性淋巴瘤：一项 2 期联盟试验。
Blood. 2018 Jan 11;131(2):182-190. doi: 10.1182/blood-2017-09-804641. Epub 2017 Oct 26.
10
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.阿卡拉布替尼（ACP-196）：一种具有独特选择性和体内药效学特征的共价布鲁顿酪氨酸激酶抑制剂。
J Pharmacol Exp Ther. 2017 Nov;363(2):240-252. doi: 10.1124/jpet.117.242909. Epub 2017 Sep 7.
Zotero 插件